Fragment screening for a protein-protein interaction inhibitor to WDR5

Matthew L. Dennis, Ben Morrow, Olan Dolezal, Anthony N. Cuzzupe, Alex Stupple, Janet Newman, John Bentley, Meghan Hattarki, Stewart D. Nuttall, Richard Foitzik, Ian P. Street, Paul A. Stupple, Brendon J. Monahan, Thomas S. Peat

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The WD40-repeat protein WDR5 scaffolds various epigenetic writers and is a critical component of the mammalian SET/MLL histone methyltransferase complex. Dysregulation of the MLL1 catalytic function is associated with mixed-lineage leukemia, and antagonism of the WDR5-MLL1 interaction by small molecules has been proposed as a therapeutic strategy for MLL-rearranged cancers. Small molecule binders of the "WIN" site of WDR5 that cause displacement from chromatin have been additionally implicated to be of broader use in cancer treatment. In this study, a fragment screen with Surface Plasmon Resonance (SPR) was used to identify a highly ligand-efficient imidazole-containing compound that is bound in the WIN site. The subsequent medicinal chemistry campaign-guided by a suite of high-resolution cocrystal structures with WDR5-progressed the initial hit to a low micromolar binder. One outcome from this study is a moiety that substitutes well for the side chain of arginine; a tripeptide containing one such substitution was resolved in a high resolution structure (1.5 Å) with a binding mode analogous to the native tripeptide. SPR furthermore indicates a similar residence time (kd = ∼0.06 s-1) for these two analogs. This novel scaffold therefore represents a possible means to overcome the potential permeability issues of WDR5 ligands that possess highly basic groups like guanidine. The series reported here furthers the understanding of the WDR5 WIN site and functions as a starting point for the development of more potent WDR5 inhibitors that may serve as cancer therapeutics.

Original languageEnglish
Article number064701
Number of pages20
JournalStructural Dynamics
Volume6
Issue number6
DOIs
Publication statusPublished - 1 Nov 2019

Cite this

Dennis, M. L., Morrow, B., Dolezal, O., Cuzzupe, A. N., Stupple, A., Newman, J., ... Peat, T. S. (2019). Fragment screening for a protein-protein interaction inhibitor to WDR5. Structural Dynamics, 6(6), [064701]. https://doi.org/10.1063/1.5122849
Dennis, Matthew L. ; Morrow, Ben ; Dolezal, Olan ; Cuzzupe, Anthony N. ; Stupple, Alex ; Newman, Janet ; Bentley, John ; Hattarki, Meghan ; Nuttall, Stewart D. ; Foitzik, Richard ; Street, Ian P. ; Stupple, Paul A. ; Monahan, Brendon J. ; Peat, Thomas S. / Fragment screening for a protein-protein interaction inhibitor to WDR5. In: Structural Dynamics. 2019 ; Vol. 6, No. 6.
@article{3db10d1554bf40368e43bc20e851e8b7,
title = "Fragment screening for a protein-protein interaction inhibitor to WDR5",
abstract = "The WD40-repeat protein WDR5 scaffolds various epigenetic writers and is a critical component of the mammalian SET/MLL histone methyltransferase complex. Dysregulation of the MLL1 catalytic function is associated with mixed-lineage leukemia, and antagonism of the WDR5-MLL1 interaction by small molecules has been proposed as a therapeutic strategy for MLL-rearranged cancers. Small molecule binders of the {"}WIN{"} site of WDR5 that cause displacement from chromatin have been additionally implicated to be of broader use in cancer treatment. In this study, a fragment screen with Surface Plasmon Resonance (SPR) was used to identify a highly ligand-efficient imidazole-containing compound that is bound in the WIN site. The subsequent medicinal chemistry campaign-guided by a suite of high-resolution cocrystal structures with WDR5-progressed the initial hit to a low micromolar binder. One outcome from this study is a moiety that substitutes well for the side chain of arginine; a tripeptide containing one such substitution was resolved in a high resolution structure (1.5 {\AA}) with a binding mode analogous to the native tripeptide. SPR furthermore indicates a similar residence time (kd = ∼0.06 s-1) for these two analogs. This novel scaffold therefore represents a possible means to overcome the potential permeability issues of WDR5 ligands that possess highly basic groups like guanidine. The series reported here furthers the understanding of the WDR5 WIN site and functions as a starting point for the development of more potent WDR5 inhibitors that may serve as cancer therapeutics.",
author = "Dennis, {Matthew L.} and Ben Morrow and Olan Dolezal and Cuzzupe, {Anthony N.} and Alex Stupple and Janet Newman and John Bentley and Meghan Hattarki and Nuttall, {Stewart D.} and Richard Foitzik and Street, {Ian P.} and Stupple, {Paul A.} and Monahan, {Brendon J.} and Peat, {Thomas S.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1063/1.5122849",
language = "English",
volume = "6",
journal = "Structural Dynamics",
issn = "2329-7778",
publisher = "AIP Publishing",
number = "6",

}

Dennis, ML, Morrow, B, Dolezal, O, Cuzzupe, AN, Stupple, A, Newman, J, Bentley, J, Hattarki, M, Nuttall, SD, Foitzik, R, Street, IP, Stupple, PA, Monahan, BJ & Peat, TS 2019, 'Fragment screening for a protein-protein interaction inhibitor to WDR5', Structural Dynamics, vol. 6, no. 6, 064701. https://doi.org/10.1063/1.5122849

Fragment screening for a protein-protein interaction inhibitor to WDR5. / Dennis, Matthew L.; Morrow, Ben; Dolezal, Olan; Cuzzupe, Anthony N.; Stupple, Alex; Newman, Janet; Bentley, John; Hattarki, Meghan; Nuttall, Stewart D.; Foitzik, Richard; Street, Ian P.; Stupple, Paul A.; Monahan, Brendon J.; Peat, Thomas S.

In: Structural Dynamics, Vol. 6, No. 6, 064701, 01.11.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Fragment screening for a protein-protein interaction inhibitor to WDR5

AU - Dennis, Matthew L.

AU - Morrow, Ben

AU - Dolezal, Olan

AU - Cuzzupe, Anthony N.

AU - Stupple, Alex

AU - Newman, Janet

AU - Bentley, John

AU - Hattarki, Meghan

AU - Nuttall, Stewart D.

AU - Foitzik, Richard

AU - Street, Ian P.

AU - Stupple, Paul A.

AU - Monahan, Brendon J.

AU - Peat, Thomas S.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - The WD40-repeat protein WDR5 scaffolds various epigenetic writers and is a critical component of the mammalian SET/MLL histone methyltransferase complex. Dysregulation of the MLL1 catalytic function is associated with mixed-lineage leukemia, and antagonism of the WDR5-MLL1 interaction by small molecules has been proposed as a therapeutic strategy for MLL-rearranged cancers. Small molecule binders of the "WIN" site of WDR5 that cause displacement from chromatin have been additionally implicated to be of broader use in cancer treatment. In this study, a fragment screen with Surface Plasmon Resonance (SPR) was used to identify a highly ligand-efficient imidazole-containing compound that is bound in the WIN site. The subsequent medicinal chemistry campaign-guided by a suite of high-resolution cocrystal structures with WDR5-progressed the initial hit to a low micromolar binder. One outcome from this study is a moiety that substitutes well for the side chain of arginine; a tripeptide containing one such substitution was resolved in a high resolution structure (1.5 Å) with a binding mode analogous to the native tripeptide. SPR furthermore indicates a similar residence time (kd = ∼0.06 s-1) for these two analogs. This novel scaffold therefore represents a possible means to overcome the potential permeability issues of WDR5 ligands that possess highly basic groups like guanidine. The series reported here furthers the understanding of the WDR5 WIN site and functions as a starting point for the development of more potent WDR5 inhibitors that may serve as cancer therapeutics.

AB - The WD40-repeat protein WDR5 scaffolds various epigenetic writers and is a critical component of the mammalian SET/MLL histone methyltransferase complex. Dysregulation of the MLL1 catalytic function is associated with mixed-lineage leukemia, and antagonism of the WDR5-MLL1 interaction by small molecules has been proposed as a therapeutic strategy for MLL-rearranged cancers. Small molecule binders of the "WIN" site of WDR5 that cause displacement from chromatin have been additionally implicated to be of broader use in cancer treatment. In this study, a fragment screen with Surface Plasmon Resonance (SPR) was used to identify a highly ligand-efficient imidazole-containing compound that is bound in the WIN site. The subsequent medicinal chemistry campaign-guided by a suite of high-resolution cocrystal structures with WDR5-progressed the initial hit to a low micromolar binder. One outcome from this study is a moiety that substitutes well for the side chain of arginine; a tripeptide containing one such substitution was resolved in a high resolution structure (1.5 Å) with a binding mode analogous to the native tripeptide. SPR furthermore indicates a similar residence time (kd = ∼0.06 s-1) for these two analogs. This novel scaffold therefore represents a possible means to overcome the potential permeability issues of WDR5 ligands that possess highly basic groups like guanidine. The series reported here furthers the understanding of the WDR5 WIN site and functions as a starting point for the development of more potent WDR5 inhibitors that may serve as cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85075115707&partnerID=8YFLogxK

U2 - 10.1063/1.5122849

DO - 10.1063/1.5122849

M3 - Article

VL - 6

JO - Structural Dynamics

JF - Structural Dynamics

SN - 2329-7778

IS - 6

M1 - 064701

ER -

Dennis ML, Morrow B, Dolezal O, Cuzzupe AN, Stupple A, Newman J et al. Fragment screening for a protein-protein interaction inhibitor to WDR5. Structural Dynamics. 2019 Nov 1;6(6). 064701. https://doi.org/10.1063/1.5122849